The natural history of chronic hepatitis B virus (HBV) infection is driven by complex interactions among virological, host, ...

United Airlines Chief Executive Scott Kirby said that consumer sentiment is actually stronger than it seems.Overall, people ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Major health sector news includes GSK and Spero stopping a UTI drug trial due to early success, Brazil's bird flu cases and ...

Spero Therapeutics, Inc. (NASDAQ: SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

Shares of Spero Therapeutics SPRO more than tripled in market value yesterday after a phase III study evaluating its ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we have what it ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

ITeos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...